RxDoctor Payments Data

Anna Wiygul

Family · Oxford, MSNPI 1619496403

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 777 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.5% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,582in general payments, 2019–2025

Across 777 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Merck$999
  • Johnson & Johnson$909
  • E.r. Squibb & Sons, L.L.C.$775
  • Pfizer$639
  • Lilly USA, LLC$589
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$14,20797%
  • Education$3753%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis82$1,385
Merck47$999
Johnson & Johnson(2 entities)57$909
E.r. Squibb & Sons, L.L.C.51$775
Pfizer41$639
Lilly USA, LLC32$589
Bristol Myers Squibb29$551
Gilead27$533
AstraZeneca(2 entities)29$524
Takeda Pharmaceuticals U.S.A., Inc.21$490
Incyte Corporation22$431
Seagen Inc.22$429
Karyopharm Therapeutics Inc.8$428
Eisai Inc.23$387
Genentech USA, Inc.19$375
Pharmacyclics LLC, An Abbvie Company19$359
AbbVie15$347
GSK20$346
Exelixis Inc.20$345
Daiichi Sankyo Inc.16$330
Amgen17$289
Astellas Pharma US Inc10$214
Beigene USA, Inc.10$200
Rigel Pharmaceuticals, Inc.10$163
AVEO Pharmaceuticals, Inc.8$159
Bayer8$157
Pharmacosmos Therapeutics Inc.8$157
EMD Serono, Inc.9$147
Regeneron Healthcare Solutions, Inc.6$131
Taiho Oncology, Inc.8$129
Adaptive Biotechnologies Corporation6$128
Sanofi5$116
Tersera Therapeutics LLC5$104
Intuitive Surgical1$103
Jazz Pharmaceuticals Inc.4$98
Array Biopharma Inc5$96
Sobi, Inc4$95
Dendreon Pharmaceuticals LLC4$93
Mirati Therapeutics, Inc.5$77
G1 Therapeutics, Inc.5$74
Tempus AI, Inc3$67
Springworks Therapeutics, Inc.2$54
Caris MPI, Inc.3$46
AMAG Pharmaceuticals, Inc.3$41
Blueprint Medicines Corporation2$41
Boehringer Ingelheim2$39
Servier Pharmaceuticals LLC2$31
Pharmaessentia USA Corporation2$30
Alnylam Pharmaceuticals Inc.1$28
Puma Biotechnology, Inc.2$25
Deciphera Pharmaceuticals Inc.1$25
Recordati_rare_diseases_inc.1$23
Dova Pharmaceuticals1$20
Genmab U.S., Inc.1$19
Beone Medicines USA, Inc.1$18
Kyowa Kirin, Inc.1$18
Sanofi-aventis U.S. LLC1$17
Ipsen Biopharmaceuticals, Inc1$16
Agios Pharmaceuticals, Inc.1$16
Coherus Oncology, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,582 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$43,104
Medicare patients
326
Services billed
717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$18,746
XareltoRivaroxaban26$17,608
Exemestane21$3,896
Letrozole46$596
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen31$540
Tamoxifen Citrate30$468
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$365
Potassium Chloride37$217
Ondansetron OdtOndansetron14$198
Triamcinolone Acetonide12$186
Gabapentin31$176
Ondansetron Hcl14$87
Duloxetine Hcl12$85
Nystatin12$81
Sertraline Hcl11$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$639$18,74622 claims
Johnson & JohnsonXarelto$909$17,60826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →